https://www.selleckchem.com/products/rmc-6236.html
Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 diabetes patients with renal impairment. A total of 156 patients referred with suboptimal glycemic control were assigned to Group G (GLP-1) = 72 or Group S (SGLT-2 inhibitor)-dapagliflozin ( = 52) or empagliflozin ( = 32). Renal function was assessed every 3
Like
Comment
Share
